問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital

Division of Cardiovascular Diseases

更新時間:2025-10-18

宋亨佑
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

3Cases

2025-08-29 - 2031-12-31

Phase III

Active
A double-blind, randomized, placebo-controlled, multicenter trial was conducted to evaluate the use of Olpasiran in participants with elevated lipoprotein (a) levels to prevent the first major cardiovascular event.
  • Condition/Disease

    The risk of a first major cardiovascular event is associated with elevated lipoprotein (a) (Lp[a]).

  • Test Drug

    AMG 890 (Olpasiran)

Participate Sites
9Sites

Recruiting9Sites

2024-09-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2026-03-01 - 2030-10-09

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting4Sites